新西兰开始资助对高级肝癌进行有前途的免疫激活治疗。 New Zealand begins funding a promising immune-activating treatment for advanced liver cancer.

从2025年3月1日起,新西兰将为晚期肝癌 (HCC) 的公众患者提供TECENTRIQ (阿特祖祖马布) 与贝瓦齐祖马布结合的资金,每年可能帮助约70人. From March 1, 2025, New Zealand will fund TECENTRIQ (atezolizumab) combined with bevacizumab for public patients with advanced liver cancer (HCC), potentially helping around 70 people annually. 这种治疗通过激活免疫系统和切断肿瘤血液供应来对抗癌症,表明死亡风险降低34%,存活率提高。 This treatment combats cancer by activating the immune system and cutting off tumor blood supply, showing a 34% reduction in death risk and improved survival rates. 这一行动的目标是增加肝癌死亡率,特别是由于乙型和丙型肝炎发病率较高,影响毛利人和太平洋岛屿社区。 The move targets rising liver cancer mortality, especially affecting Māori and Pacific communities due to higher hepatitis B and C rates.